HER2 Testing Market Outlook:
HER2 Testing Market size was over USD 166.34 million in 2025 and is projected to reach USD 333.38 million by 2035, growing at around 7.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of HER2 testing is evaluated at USD 177.12 million.
The market for HER2 testing is slated to grow at a rate that is proportionate to research and development in cancer diagnostic technologies, which will lead to more sophisticated applications for HER2 testing and cancer screening. The United States alone has a sizable patient pool for breast cancer, with around 62800 occurrences of in situ breast cancer, 1980 of which are in men, and approximately 15% of cases dying from rising rates of breast cancer, according to data from the American Society of Clinical Oncology (ASCO).
In addition to these, the popularity of HER2 testing for breast cancer screening is predicted to soar due to the expanding support from both public and private organizations, as well as reimbursement policies for breast biopsy and diagnosis. It is predicted that the combination of the Inform HER2 Dual ISH test and the SPoT-Light HER2 CISH test will provide an accurate and affordable solution for breast HER2 testing.
